Vaxart (OTCMKTS:VXRT) Stock Breaks Below Two Hundred Day Moving Average – Should You Sell?

Vaxart, Inc. (OTCMKTS:VXRT)’s stock price crossed below its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $0.60 and traded as low as $0.4601. Vaxart shares last traded at $0.4845, with a volume of 334,853 shares.

Analysts Set New Price Targets

Separately, Zacks Research upgraded shares of Vaxart to a “hold” rating in a report on Thursday, July 9th. One investment analyst has rated the stock with a Hold rating, According to MarketBeat.com, the company has a consensus rating of “Hold”.

Vaxart Trading Down 5.8%

The company has a 50-day moving average price of $0.51 and a two-hundred day moving average price of $0.60. The stock has a market cap of $110.15 million, a P/E ratio of 2.83 and a beta of 1.06.

Vaxart (OTCMKTS:VXRT) last posted its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.06. Vaxart had a net margin of 15.88% and a return on equity of 53.04%. The company had revenue of $27.18 million during the quarter, compared to analyst estimates of $26.21 million. As a group, equities analysts forecast that Vaxart, Inc. will post -0.68 earnings per share for the current fiscal year.

About Vaxart

Vaxart, Inc is a clinical-stage biotechnology company developing vaccines designed to be administered orally in tablet form rather than by injection. The company’s platform is intended to stimulate immune responses in the nose, mouth and gastrointestinal tract, in addition to systemic immunity, with the goal of improving vaccine administration and potentially limiting the spread of respiratory and enteric infections.

Vaxart’s pipeline has included oral vaccine candidates for norovirus, seasonal influenza and coronavirus infections.